Faslodex (fulvestrant) - Risk Of Unnecessary Therapy Modification Due To Falsely Elevated Estradiol Levels

FASLODEX Recall Summary Faslodex (fulvestrant), a breast cancer medication distributed across Canada, is being recalled because it can cause falsely elevated estradiol hormone levels in blood tests. This false elevation may lead doctors to unnecessarily change a patient's treatment plan based on inaccurate test results. The recall affects all patients currently taking or prescribed this medication in Canada.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-10-18

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/26cd96e6-ef9e-46d0-8cea-97f4cdd15d40